Moderna Inc (MRNA)

Return on equity (ROE)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	-4,714,000	8,362,000	12,202,000	-747,000	-514,000
Total stockholders’ equity	US$ in thousands	13,854,000	19,123,000	14,145,000	2,561,000	1,175,000
ROE		-34.03%	43.73%	86.26%	-29.17%	-43.74%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $-4,714,000K ÷ $13,854,000K
= -34.03%

Looking at Moderna Inc's return on equity (ROE) over the past five years, there has been significant fluctuation in the company's performance in this area.

In 2023, the ROE was reported at -34.03%, indicating that the company experienced a negative return on equity, reflecting that its net income was not generating sufficient returns for its shareholders given the equity invested. This is a notable decline from the previous year when the ROE was at 43.73%.

In 2022, the ROE improved significantly to 43.73%, showing that Moderna was able to generate a decent return on the equity invested in the company during that year. This positive trend continued from 2021 when the ROE was at a high of 86.26%, indicating the company's ability to generate meaningful profits relative to shareholder equity.

However, in 2020 and 2019, Moderna reported negative ROE figures of -29.17% and -43.75% respectively. These results suggest that the company struggled to generate profits or efficiently utilize shareholder equity during those years, leading to a lower or negative return for shareholders.

Overall, the fluctuation in Moderna Inc's ROE over the past five years indicates that the company's profitability and efficiency in generating returns for shareholders have varied. It would be important for stakeholders to closely monitor the company's financial performance and management strategies to ensure sustainable growth and value creation.